Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial

We investigated the effects of aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril on urinary albumin excretion, endothelial function and inflammatory activity in hypertensive type II diabetic individuals. A total of 70 hypertensive type II diabetic individuals were treated with three antihypertensive strategies in a randomized, double- blind, doubledummy design. Blood pressure was titrated to levels below 130/ 85 mmHg or a decrease in systolic pressure of 10% with a diastolic pressure below 85mmHg. After titration, patients were treated for 12 months. Mean blood pressures changed from 157/ 93, 151/ 94 and 149/ 93 at baseline to 135/ 80, 135/ 82 and 131/ 80 mmHg after titration in the hydrochlorothiazide ( n = 24), candesartan ( n = 24) and lisinopril ( n = 22) groups. About 70% reached target blood pressures. However, only 45% had blood pressures < 130/ 85mmHg. Urinary albumin excretion and levels of soluble vascular cell adhesion molecule- 1 and intercellular adhesion molecule- 1 decreased ( GEE regression coefficients, - 2.40 mg/ 24 h ( P < 0.001), - 85 ng/ ml ( P = 0.01) and - 50 ng/ ml ( P = 0.02)), but brachial artery endothelium-dependent and - independent vasodilation and levels of von Willebrand factor and C- reactive protein did not change ( GEE regression coefficients, 0.21 mm ( P = 0.07), 0.04 mm ( P = 0.43), 0.04 IU/ ml ( P = 0.33) and - 1.15 mg/ l ( P = 0.64)). No differences in outcome variables between treatment groups were observed. These data show that achievement of target blood pressures below 130/ 85mmHg in hypertensive type II diabetes is difficult. Aggressive antihypertensive therapy can improve urinary albumin excretion, endothelial function and inflammatory activity in hypertensive type II diabetic individuals, regardless of the type of antihypertensive therapy used.